CD154 gene therapy (Tragen)

N/A

Report date: 2023/10/26 16:02:00

Base Information

Drug NameCD154 gene therapy (Tragen)
Drug Alias NameAd-ISF154ISF-154
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionCD40 ligand stimulants
TargetsCD40 ligand
Therapy Area/IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of California San Diego
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of California San DiegoTragen Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A